Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors

Authors: Véronique Ouellet, Tak Hay Ling, Karine Normandin, Jason Madore, Christian Lussier, Véronique Barrès, Dimcho Bachvarov, Claudine Rancourt, Patricia N Tonin, Diane M Provencher, Anne-Marie Mes-Masson

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Serous epithelial ovarian tumors can be subdivided into benign (BOV), low malignant potential (LMP) or borderline and invasive (TOV) tumors. Although the molecular characteristics of serous BOV, LMP and low grade (LG) TOV tumors has been initiated, definitive immunohistochemical markers to distinguish between these tumor types have not been defined.

Methods

In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).

Results

Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.

Conclusion

This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.
Appendix
Available only for authorised users
Literature
1.
Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y: Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007, 5 (1): 35-44. 10.3121/cmr.2007.702.CrossRefPubMedPubMedCentral
2.
Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007, 19 (1): 3-9.CrossRefPubMed
3.
Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN: Pathology and classification of ovarian tumors. Cancer. 2003, 97 (10 Suppl): 2631-2642. 10.1002/cncr.11345.CrossRefPubMed
4.
Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001, 22 (2): 255-288. 10.1210/er.22.2.255.PubMed
5.
Scully RE: Common epithelial tumors of borderline malignancy (carcinomas of low malignant potential). Bull Cancer. 1982, 69 (3): 228-238.PubMed
6.
Dietel M, Hauptmann S: Serous tumors of low malignant potential of the ovary. 1. Diagnostic pathology. Virchows Arch. 2000, 436 (5): 403-412. 10.1007/s004280050467.CrossRefPubMed
7.
Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol. 2005, 18 (Suppl 2): S33-50. 10.1038/modpathol.3800307.CrossRefPubMed
8.
Burger CW, Prinssen HM, Baak JP, Wagenaar N, Kenemans P: The management of borderline epithelial tumors of the ovary. Int J Gynecol Cancer. 2000, 10 (3): 181-197. 10.1046/j.1525-1438.2000.010003181.x.CrossRefPubMed
9.
Tavassoli FA: Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion). Mod Pathol. 1988, 1 (6): 407-414.PubMed
10.
Silverberg SG: Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol. 2000, 19 (1): 7-15. 10.1097/00004347-200001000-00003.CrossRefPubMed
11.
Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the ovary. Int J Gynaecol Obstet. 2003, 83 (Suppl 1): 135-166. 10.1016/S0020-7292(03)90118-4.CrossRefPubMed
12.
Malpica A: Grading of ovarian cancer: a histotype-specific approach. Int J Gynecol Pathol. 2008, 27 (2): 175-181.PubMed
13.
Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004, 164 (5): 1511-1518.CrossRefPubMed
14.
Shih Ie M, Kurman RJ: Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005, 11 (20): 7273-7279. 10.1158/1078-0432.CCR-05-0755.CrossRefPubMed
15.
de Souza PL, Friedlander ML: Prognostic factors in ovarian cancer. Hematol Oncol Clin North Am. 1992, 6 (4): 761-782.PubMed
16.
Bell DA, Scully RE: Ovarian serous borderline tumors with stromal microinvasion: a report of 21 cases. Hum Pathol. 1990, 21 (4): 397-403. 10.1016/0046-8177(90)90201-F.CrossRefPubMed
17.
Hanselaar AG, Vooijs GP, Mayall B, Ras-Zeijlmans GJ, Chadha-Ajwani S: Epithelial markers to detect occult microinvasion in serous ovarian tumors. Int J Gynecol Pathol. 1993, 12 (1): 20-27.CrossRefPubMed
18.
Jones MB: Borderline ovarian tumors: current concepts for prognostic factors and clinical management. Clin Obstet Gynecol. 2006, 49 (3): 517-525. 10.1097/00003081-200609000-00011.CrossRefPubMed
19.
Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ: Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol. 2004, 35 (8): 934-948. 10.1016/j.humpath.2004.03.005.CrossRefPubMed
20.
Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR: Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am J Surg Pathol. 2005, 29 (6): 707-723. 10.1097/01.pas.0000164030.82810.db.CrossRefPubMed
21.
Kennedy AW, Hart WR: Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma. Cancer. 1996, 78 (2): 278-286. 10.1002/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T.CrossRefPubMed
22.
Young RH, Scully RE: Pathology of epithelial tumors. Hematol Oncol Clin North Am. 1992, 6 (4): 739-760.PubMed
23.
Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, Oliva E, Kajdacsy-Balla A, Berman DM, Copeland LJ: Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum Pathol. 2004, 35 (8): 918-933. 10.1016/j.humpath.2004.03.004.CrossRefPubMed
24.
Hoskins WJ, Young RC, Markman M, Perez AP, Barakat RR, Randall M: Principles and Practice of Gynecologic Oncology. 2005, Philadelphie: Lippincott Williams & Wilkins, 4
25.
Nayar R, Siriaunkgul S, Robbins KM, McGowan L, Ginzan S, Silverberg SG: Microinvasion in low malignant potential tumors of the ovary. Hum Pathol. 1996, 27 (6): 521-527. 10.1016/S0046-8177(96)90156-2.CrossRefPubMed
26.
Burks RT, Sherman ME, Kurman RJ: Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol. 1996, 20 (11): 1319-1330. 10.1097/00000478-199611000-00003.CrossRefPubMed
27.
Prat J, De Nictolis M: Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002, 26 (9): 1111-1128. 10.1097/00000478-200209000-00002.CrossRefPubMed
28.
Eichhorn JH, Bell DA, Young RH, Scully RE: Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999, 23 (4): 397-409. 10.1097/00000478-199904000-00004.CrossRefPubMed
29.
Seidman JD, Ronnett BM, Kurman RJ: Pathology of borderline (low malignant potential) ovarian tumours. Best Pract Res Clin Obstet Gynaecol. 2002, 16 (4): 499-512. 10.1053/beog.2002.0300.CrossRefPubMed
30.
Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer. 2006, 119 (3): 599-607. 10.1002/ijc.21902.CrossRefPubMed
31.
Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: SET complex in serous epithelial ovarian cancer. Int J Cancer. 2006, 119 (9): 2119-2126. 10.1002/ijc.22054.CrossRefPubMed
32.
Ouellet V, Le Page C, Madore J, Guyot MC, Barres V, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM: An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer. Cancer. 2007
33.
Warrenfeltz S, Pavlik S, Datta S, Kraemer ET, Benigno B, McDonald JF: Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. Mol Cancer. 2004, 3 (1): 27-10.1186/1476-4598-3-27.CrossRefPubMedPubMedCentral
34.
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, et al: Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005, 24 (6): 1053-1065. 10.1038/sj.onc.1208298.CrossRefPubMed
35.
Ouellet V, Provencher DM, Maugard CM, Le Page C, Ren F, Lussier C, Novak J, Ge B, Hudson TJ, Tonin PN, et al: Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene. 2005, 24 (29): 4672-4687. 10.1038/sj.onc.1208214.CrossRefPubMed
36.
Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, et al: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005, 65 (22): 10602-10612. 10.1158/0008-5472.CAN-05-2240.CrossRefPubMed
37.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell. 1993, 75 (4): 817-825. 10.1016/0092-8674(93)90500-P.CrossRefPubMed
38.
Kim TK: In vitro transcriptional activation of p21 promoter by p53. Biochem Biophys Res Commun. 1997, 234 (2): 300-302. 10.1006/bbrc.1997.6637.CrossRefPubMed
39.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature. 1993, 366 (6456): 701-704. 10.1038/366701a0.CrossRefPubMed
40.
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75 (4): 805-816. 10.1016/0092-8674(93)90499-G.CrossRefPubMed
41.
Boulaire J, Fotedar A, Fotedar R: The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris). 2000, 48 (3): 190-202.
42.
Macaluso M, Montanari M, Cinti C, Giordano A: Modulation of cell cycle components by epigenetic and genetic events. Semin Oncol. 2005, 32 (5): 452-457. 10.1053/j.seminoncol.2005.07.009.CrossRefPubMed
43.
Buchynska LG, Nesina IP, Yurchenko NP, Bilyk OO, Grinkevych VN, Svintitsky VS: Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors. Exp Oncol. 2007, 29 (1): 49-53.PubMed
44.
Terauchi F, Okamoto A, Nagashima T, Kobayashi Y, Moritake T, Yamamoto Y, Takakura S, Iwaki S, Ogura H: Clinical significance of p21(WAF1/CIP1) and p53 expression in serous cystadenocarcinoma of the ovary. Oncol Rep. 2005, 14 (2): 363-368.PubMed
45.
Plisiecka-Halasa J, Karpinska G, Szymanska T, Ziolkowska I, Madry R, Timorek A, Debniak J, Ulanska M, Jedryka M, Chudecka-Glaz A, et al: P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol. 2003, 14 (7): 1078-1085. 10.1093/annonc/mdg299.CrossRefPubMed
46.
Vassilopoulos I, Korkolopoulou P, Konstantinidou AE, Patsouris E, Eftichiadis C, Thymara I, Perdiki M, Pavlakis K, Agapitos E, Davaris PS: Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas. Histol Histopathol. 2003, 18 (3): 761-770.PubMed
47.
Palazzo JP, Monzon F, Burke M, Hyslop T, Dunton C, Barusevicius A, Capuzzi D, Kovatich AJ: Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors. Hum Pathol. 2000, 31 (6): 698-704. 10.1053/hupa.2000.7641.CrossRefPubMed
48.
Bukholm IK, Nesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch. 2000, 436 (3): 224-228. 10.1007/s004280050034.CrossRefPubMed
49.
Shoji T, Tanaka F, Takata T, Yanagihara K, Otake Y, Hanaoka N, Miyahara R, Nakagawa T, Kawano Y, Ishikawa S, et al: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol. 2002, 20 (18): 3865-3871. 10.1200/JCO.2002.09.147.CrossRefPubMed
50.
Tamura M, Sawabata N, Kobayashi S, Umezu H, Seki N, Yoshii N, Karube Y, Araki O, Ishihama H, Nagai S, et al: Prognostic significance of p21 protein expression in patients with pulmonary squamous cell carcinoma following induction chemotherapy. Ann Thorac Cardiovasc Surg. 2007, 13 (1): 9-14.PubMed
51.
Kapranos N, Stathopoulos GP, Manolopoulos L, Kokka E, Papadimitriou C, Bibas A, Yiotakis J, Adamopoulos G: p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res. 2001, 21 (1B): 521-528.PubMed
52.
Migaldi M, Sgambato A, Garagnani L, Ardito R, Ferrari P, De Gaetani C, Cittadini A, Trentini GP: Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers. Clin Cancer Res. 2000, 6 (8): 3131-3138.PubMed
53.
Mattioli E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM, Cevenini G, et al: Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer. J Cell Physiol. 2007, 210 (1): 183-191. 10.1002/jcp.20833.CrossRefPubMed
54.
Fauvet R, Poncelet C, Hugol D, Lavaur A, Feldmann G, Darai E: Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours. Virchows Arch. 2003, 443 (1): 38-43. 10.1007/s00428-003-0813-3.CrossRefPubMed
55.
Goto M, Tsukamoto T, Inada K, Mizoshita T, Ogawa T, Terada A, Hyodo I, Shimozato K, Hasegawa Y, Tatematsu M: Loss of p21WAF1/CIP1 expression in invasive fronts of oral tongue squamous cell carcinomas is correlated with tumor progression and poor prognosis. Oncol Rep. 2005, 14 (4): 837-846.PubMed
56.
Edmonston TB, Cuesta KH, Burkholder S, Barusevicius A, Rose D, Kovatich AJ, Boman B, Fry R, Fishel R, Palazzo JP: Colorectal carcinomas with high microsatellite instability: defining a distinct immunologic and molecular entity with respect to prognostic markers. Hum Pathol. 2000, 31 (12): 1506-1514. 10.1053/hupa.2000.20383.CrossRefPubMed
57.
Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS: Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. J Pathol. 2006, 210 (2): 147-154. 10.1002/path.2030.CrossRefPubMed
58.
Lee H, Park G, Jung JH, Ahn WS, Lee JM, Kim BK, Kang CS: Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors. Int J Gynecol Cancer. 2005, 15 (3): 453-461. 10.1111/j.1525-1438.2005.15308.x.CrossRefPubMed
59.
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 2004, 101 (25): 9309-9314. 10.1073/pnas.0401994101.CrossRefPubMedPubMedCentral
60.
Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, et al: Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet. 2004, 149 (2): 98-106. 10.1016/S0165-4608(03)00300-5.CrossRefPubMed
61.
Wikman H, Kettunen E, Seppanen JK, Karjalainen A, Hollmen J, Anttila S, Knuutila S: Identification of differentially expressed genes in pulmonary adenocarcinoma by using cDNA array. Oncogene. 2002, 21 (37): 5804-5813. 10.1038/sj.onc.1205726.CrossRefPubMed
62.
Koon N, Schneider-Stock R, Sarlomo-Rikala M, Lasota J, Smolkin M, Petroni G, Zaika A, Boltze C, Meyer F, Andersson L, et al: Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut. 2004, 53 (2): 235-240. 10.1136/gut.2003.021238.CrossRefPubMedPubMedCentral
63.
64.
Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih Ie M: Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005, 29 (2): 218-224. 10.1097/01.pas.0000146025.91953.8d.CrossRefPubMed
65.
Scott M, McCluggage WG: Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data. Histol Histopathol. 2006, 21 (1): 81-92.PubMed
66.
Kurman RJ, Seidman JD, Shih IM: Serous borderline tumours of the ovary. Histopathology. 2005, 47 (3): 310-315. 10.1111/j.1365-2559.2005.02186.x.CrossRefPubMed
67.
Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol. 2003, 200 (3): 327-335. 10.1002/path.1364.CrossRefPubMed
Metadata
Title
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
Authors
Véronique Ouellet
Tak Hay Ling
Karine Normandin
Jason Madore
Christian Lussier
Véronique Barrès
Dimcho Bachvarov
Claudine Rancourt
Patricia N Tonin
Diane M Provencher
Anne-Marie Mes-Masson
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-346

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Expression of the RON receptor tyrosine kinase and its association with gastric carcinoma versus normal gastric tissues

Research article

Cancer Trajectories at the End of Life: is there an effect of age and gender?

Research article

Geographical spread of gastrointestinal tract cancer incidence in the Caspian Sea region of Iran: Spatial analysis of cancer registry data

Research article

Father's occupational exposure to carcinogenic agents and childhood acute leukemia: a new method to assess exposure (a case-control study)

Research article

Muscle invasive bladder cancer in Upper Egypt: the shift in risk factors and tumor characteristics

Research article

Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits